Literature DB >> 26307211

Features of Metabolic Syndrome and Its Associated Factors during Highly Active Antiretroviral Therapy in Ouagadougou (Burkina Faso).

Oumar Guira1, Hervé Tiéno2, Arnaud Eric Diendéré3, Yempabou Sagna3, Ismael Diallo2, Bertille Yaméogo3, Lassané Zoungrana3, Tènè Marceline Yaméogo4, Réné Bognounou3, Joseph Youssouf Drabo2.   

Abstract

BACKGROUND: To study the features of metabolic syndrome (MS) and its associated factors during highly active antiretroviral therapy (HAART), in Ouagadougou.
METHODS: It was a cross-sectional study from March to November 2011 in Yalgado Ouédraogo hospital. A nonprobability sample of adults receiving antiretroviral drugs for at least 6 months was studied. Pregnancy, ascites, or abdominal mass were noninclusion criteria. Metabolic syndrome met the criteria of International Diabetes Federation 2005.
RESULTS: The authors studied 300 patients. Metabolic syndrome was diagnosed in 54 (18%) patients: mean age 44.8 ± 7.4 years, sex ratio 0.17, and mean duration of HAART 71 ± 30.9 months. The current anomaly of MS was low high-density lipoprotein (HDL)-cholesterol in 37 patients (68.5%), and the common profile of MS was high waist circumference + low HDL-cholesterol + abnormal blood pressure (29.6%). Associated factors were protease inhibitor regimens (P = .000), female gender (P = .004), age > 42 years (P = .001), and lipodystrophy (P = .01).
CONCLUSION: Cardiovascular risks should be regarded during the care of HIV-infected patients.
© The Author(s) 2015.

Entities:  

Keywords:  Burkina Faso; HAART; HIV/AIDS; metabolic syndrome

Mesh:

Substances:

Year:  2015        PMID: 26307211     DOI: 10.1177/2325957415601503

Source DB:  PubMed          Journal:  J Int Assoc Provid AIDS Care        ISSN: 2325-9574


  13 in total

1.  Metabolic Syndrome Among Antiretroviral Therapy-Naive Versus Experienced HIV-Infected Patients Without Preexisting Cardiometabolic Disorders in Western Kenya.

Authors:  Alfred Osoti; Tecla M Temu; Nicholas Kirui; Edmond K Ngetich; Jemima H Kamano; Stephanie Page; Carey Farquhar; Gerald S Bloomfield
Journal:  AIDS Patient Care STDS       Date:  2018-06       Impact factor: 5.078

2.  Predictors of Metabolic Syndrome Among People Living with HIV in Gedeo-Zone, Southern-Ethiopia: A Case-Control Study.

Authors:  Girma Tenkolu Bune; Alemayehu Worku Yalew; Abera Kumie
Journal:  HIV AIDS (Auckl)       Date:  2020-10-06

Review 3.  Hypertension Is a Key Feature of the Metabolic Syndrome in Subjects Aging with HIV.

Authors:  Raquel Martin-Iguacel; Eugènia Negredo; Robert Peck; Nina Friis-Møller
Journal:  Curr Hypertens Rep       Date:  2016-06       Impact factor: 5.369

Review 4.  Diabetes, metabolic syndrome and dyslipidemia in people living with HIV in Africa: re-emerging challenges not to be forgotten.

Authors:  Nazik Elmalaika Husain; Sufian K Noor; Wadie M Elmadhoun; Ahmed O Almobarak; Heitham Awadalla; Clare L Woodward; Dushyant Mital; Mohamed H Ahmed
Journal:  HIV AIDS (Auckl)       Date:  2017-11-08

5.  Adverse effects of antiretroviral therapy in pregnant women infected with HIV in Brazil from 2000 to 2015: a cohort study.

Authors:  Adriane M Delicio; Giuliane J Lajos; Eliana Amaral; Fabia Lopes; Fernanda Cavichiolli; Isabeli Myioshi; Helaine Milanez
Journal:  BMC Infect Dis       Date:  2018-09-27       Impact factor: 3.090

6.  Prevalence of metabolic syndrome among HIV-positive and HIV-negative populations in sub-Saharan Africa-a systematic review and meta-analysis.

Authors:  Olamide O Todowede; Solange Z Mianda; Benn Sartorius
Journal:  Syst Rev       Date:  2019-01-03

7.  Metabolic Control and Determinants Among HIV-Infected Type 2 Diabetes Mellitus Patients Attending a Tertiary Clinic in Botswana.

Authors:  Godfrey Mutashambara Rwegerera; Dorothea H P Shailemo; Yordanka Pina Rivera; Kathryn O Mokgosi; Portia Bale; Taibat Aderonke Oyewo; Bruno Diaz Luis; Dereje Habte; Brian Godman
Journal:  Diabetes Metab Syndr Obes       Date:  2021-01-11       Impact factor: 3.168

8.  Prevalence of low high-density lipoprotein among young adults receiving antiretroviral therapy in Zambia: An opportunity to consider non-communicable diseases in resource-limited settings.

Authors:  Benson M Hamooya; Patrick Musonda; Wilbroad Mutale; Sepiso K Masenga; Hikabasa Halwiindi; Katongo H Mutengo; Kaseya O R Chiyeñu; Gershom Chongwe; John R Koethe; Loren Lipworth; Douglas C Heimburger
Journal:  PLoS One       Date:  2021-02-16       Impact factor: 3.240

Review 9.  Chronic hepatitis B-associated liver disease in the context of human immunodeficiency virus co-infection and underlying metabolic syndrome.

Authors:  Edina Amponsah-Dacosta; Cynthia Tamandjou Tchuem; Motswedi Anderson
Journal:  World J Virol       Date:  2020-12-15

Review 10.  HIV, Antiretroviral Therapy and Metabolic Alterations: A Review.

Authors:  Huseyin Ekin Ergin; Evelyn E Inga; Tun Zan Maung; Mehwish Javed; Safeera Khan
Journal:  Cureus       Date:  2020-05-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.